Aprea Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Aprea Therapeutics, Inc. (APRE) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $31.87 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-05-13
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $31.87M.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$3.58M, a 133.21% decline year-over-year.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $10.77M, a 398.21% increase year-over-year.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $2.16M.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was -$8.25M, a 760.50% decline from fiscal 2024.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $1.25M.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$7.13M.
- Aprea Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$24.33M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | $31.87M 10-Q · filed 2026-05-13 | ||||
| 2025-12-31 | -$8.25M 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | -$9.13M 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | -$6.32M 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | -$3.58M 10-Q · filed 2026-05-13 | ||||
| 2024-12-31 | $1.25M 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | $4.63M 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | $7.10M 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | $10.77M 10-Q · filed 2025-05-14 | ||||
| 2023-12-31 | -$7.13M 10-K · filed 2025-03-25 | ||||
| 2023-09-30 | -$3.38M 10-Q · filed 2024-11-07 | ||||
| 2023-06-30 | -$1.06M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | $2.16M 10-Q · filed 2024-05-14 | ||||
| 2022-12-31 | -$24.33M 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | -$20.41M 10-Q · filed 2023-11-09 | ||||
| 2022-06-30 | -$14.40M 10-Q · filed 2023-08-10 | ||||
| 2022-03-31 | -$5.50M 10-Q · filed 2023-05-15 | ||||
| 2021-12-31 | -$35.94M 10-K · filed 2024-03-26 | ||||
| 2021-09-30 | -$27.42M 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | -$19.27M 10-Q · filed 2022-08-12 | -$19.27M 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | -$11.52M 10-Q · filed 2022-05-16 | ||||
| 2020-12-31 | -$41.68M 10-K · filed 2023-03-30 | ||||
| 2020-09-30 | -$28.46M 10-Q · filed 2021-11-08 | ||||
| 2020-06-30 | -$17.04M 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | -$7.52M 10-Q · filed 2021-05-06 | ||||
| 2019-12-31 | $65.84M 10-K · filed 2022-03-15 | ||||
| 2019-09-30 | -$10.61M 10-Q · filed 2020-11-06 | ||||
| 2019-06-30 | -$4.18M 10-Q · filed 2020-08-11 | ||||
| 2019-03-31 | $1.24M 10-Q · filed 2020-05-15 | ||||
| 2018-12-31 | $41.11M 10-K · filed 2021-03-16 | ||||
| 2018-09-30 | -$11.40M 10-Q · filed 2019-11-14 | ||||
| 2017-12-31 | $9.34M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |